newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2- Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022- Initial data from TC-510 Phase 1/2 trial anticipated in 2H 2022- Sele